Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             131 results found
no title author magazine year volume issue page(s) type
1 Antitumor effects of bisphosphonates: Promising preclinical evidence Guise, Theresa A.
 2008
 34 S1 p. S19-S24
6 p.
 article
2 Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies Coleman, Robert E.
 2008
 34 S1 p. S31-S42
12 p.
 article
3 CIBD VII Schedule of Events 2008
 34 S1 p. S2-
1 p.
 article
4 Editorial board 2008
 34 S1 p. IFC-
1 p.
 article
5 Emerging role of bisphosphonates in the clinic—Antitumor activity and prevention of metastasis to bone Lipton, Allan
 2008
 34 S1 p. S25-S30
6 p.
 article
6 Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group Reid, David M.
 2008
 34 S1 p. S3-S18
16 p.
 article
7 OC9. A role for B cell suppression in a pre-clinical model of multiple myeloma Fowler, Jessica
 2008
 34 S1 p. 53-
1 p.
 article
8 OC13. Development of the European organization for research and treatment of cancer bone metastases module (BMM) (EORTC QLQ-BM22) Hird, Amanda
 2008
 34 S1 p. 11-12
2 p.
 article
9 OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) Singh, Shalini
 2008
 34 S1 p. 10-11
2 p.
 article
10 OC2. Efficacy, pharmacokinetics, and safety of a cathepsin K (Cat K) inhibitor in the suppression of bone resorption in women with breast cancer and established bone 2 Wynne, Christopher
 2008
 34 S1 p. 49-50
2 p.
 article
11 OC6. Endo180 function in metastatic prostate cancer bone lesions Kogianni, Giolanta
 2008
 34 S1 p. 51-
1 p.
 article
12 OC8. Essential role of host bone marrow-derived stromal cells in the initial establishment and progression of multiple myeloma Fowler, Jessica
 2008
 34 S1 p. 52-
1 p.
 article
13 OC3. Farnesoid X receptor (FXR): A new marker for the prediction of bone metastases in breast cancer Journe, Fabrice
 2008
 34 S1 p. 50-
1 p.
 article
14 OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma Heath, Debby
 2008
 34 S1 p. 52-
1 p.
 article
15 OC4. Number and sites of bone lesions and history of skeletal-related events (SREs): Do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)? Saad, Fred
 2008
 34 S1 p. 50-51
2 p.
 article
16 OC14. Osteolysis and the generation of osteoclast-myeloma hybrid cells are related to the myeloma cell-induced collapse of the vascular bone remodeling compartments Andersen, Thomas Levin
 2008
 34 S1 p. 11-
1 p.
 article
17 OC15. Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer Winter, Matthew
 2008
 34 S1 p. 12-13
2 p.
 article
18 OC5. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the ARIBON study Lester, James
 2008
 34 S1 p. 51-52
2 p.
 article
19 OC10. Prognosis and skeletal disease course in patients with bone metastases from breast cancer (BC) and normal baseline levels of N-telopeptide of type I collagen (NTX) Lipton, Allan
 2008
 34 S1 p. 10-
1 p.
 article
20 OC12. Specific inhibition of the VEGF homolog placental growth factor is protective against osteolytic bone metastasis in mice Coenegrachts, Lieve
 2008
 34 S1 p. 11-
1 p.
 article
21 OC1. Translating a novel urine test for early detection and accurate assessment of bone abnormalities Hillegonds, Darren
 2008
 34 S1 p. 49-
1 p.
 article
22 P5. A dual osteoclastic and metalloproteolytic mechanism is required for bone colonization in lung cancer metastasis Luis-Ravelo, Diego
 2008
 34 S1 p. 14-15
2 p.
 article
23 P17. A humanized model of breast cancer metastasis revealing a human-specific metastasis gene signature Goldstein, Robert
 2008
 34 S1 p. 19-
1 p.
 article
24 P58. An etidronate–aracytidine conjugate inhibits osteolysis and allodynia in a rodent model of prostate cancer induced bone disease Karpeisky, Alexander
 2008
 34 S1 p. 43-44
2 p.
 article
25 P6. Anti-resorptive and potential anti-invasion effects of a cathepsin K inhibitor in the treatment of breast cancer-induced bone metastasis Leung, Patrick
 2008
 34 S1 p. 14-
1 p.
 article
26 P3. A soluble activin type II receptor prevents the development of myeloma bone disease Chantry, Andrew
 2008
 34 S1 p. 13-14
2 p.
 article
27 P20. Autotaxin promotes metastasis dissemination of breast cancer cells David, Marion
 2008
 34 S1 p. 20-21
2 p.
 article
28 P28. Biological prerequisites for heterotypic fusion between myeloma cells and osteoclasts Kupisiewicz, Katarzyna
 2008
 34 S1 p. 23-24
2 p.
 article
29 P41. Bone cancer pain: The crosstalk between prostate tumour cells and osteocytes upregulates expression and release of pain mediators Pyerin, Walter
 2008
 34 S1 p. 29-30
2 p.
 article
30 P42. Bone cell reactions to cancer stress: Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo Ackermann, Karin
 2008
 34 S1 p. 29-
1 p.
 article
31 P67. Bone mineral density in men on long term androgen deprivation therapy for prostate cancer Button, Mick
 2008
 34 S1 p. 32-33
2 p.
 article
32 P74. Bone scan imaging before and after intravenous bisphosphonate therapy for osseous metastases from breast cancer Van Poznak, Catherine
 2008
 34 S1 p. 35-
1 p.
 article
33 P70. Bony metastases in renal cell carcinoma – An audit of patterns of disease and bisphosphonate use in patients treated in Leeds, UK Clarke, Katy
 2008
 34 S1 p. 33-34
2 p.
 article
34 P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions Ottewell, Penelope
 2008
 34 S1 p. 12-
1 p.
 article
35 P40. Calcium-sensing receptor mediates the effect of elevated extracellular calcium concentrations on PTHrP secretion and expression in human lung squamous cell carcinoma lines Lorch, Gwendolen
 2008
 34 S1 p. 29-
1 p.
 article
36 P43. Cells of the osteoblast lineage increase the expression of bone-related and invasiveness genes in breast cancer cells IdBoufker, Hichame
 2008
 34 S1 p. 30-31
2 p.
 article
37 P59. CT-based structural rigidity reflects treatment response in an osteolytic rat model Nazarian, Ara
 2008
 34 S1 p. 44-
1 p.
 article
38 P69. Determining relevant quality of life issues for bone metastases patients: Differences in perspectives Hird, Amanda
 2008
 34 S1 p. 33-
1 p.
 article
39 P14. Development and characterization of a new renal cell carcinoma (RCC) bone metastasis mouse model Strube, Anne
 2008
 34 S1 p. 17-
1 p.
 article
40 P72. Dexamethasone for the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone metastases: A phase II study van Draanen, Jenna
 2008
 34 S1 p. 34-
1 p.
 article
41 P10. Disease modeling and tissue engineering: Breast cancer metastasis to bone Reagan, Michaela
 2008
 34 S1 p. 16-
1 p.
 article
42 P65. Efficacy of second-line zoledronate for bone metastases of breast cancer after first-line treatment with pamidronate Miura, Hiroyoshi
 2008
 34 S1 p. 80-
1 p.
 article
43 P54. Evaluating the Wilms’ tumour antigen 1 as a target for the immunotherapy of prostate cancer King, Judy
 2008
 34 S1 p. 40-
1 p.
 article
44 P11. Fly to mouse: A new approach to cancer metastasis Heller, Emanuela
 2008
 34 S1 p. 16-17
2 p.
 article
45 P77. Guided bone regeneration for bisphosphonate-induced osteonecrosis of the jaws Mouret, Pierre
 2008
 34 S1 p. 84-
1 p.
 article
46 P22. Host-derived MMP9 promotes progression of multiple myeloma in vivo Edwards, Claire
 2008
 34 S1 p. 21-
1 p.
 article
47 P16. Hypoxia and breast cancer bone metastasis: HIF-1α enhances TGF-β signaling and expression of prometastatic factors CXCR4 and VEGF Kingsley, Lauren
 2008
 34 S1 p. 18-
1 p.
 article
48 P61. Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC) Coleman, Robert
 2008
 34 S1 p. 28-29
2 p.
 article
49 P23. Inhibitory effects of baicalein, baicalin and wogonin on osteolytic bone metastasis of breast cancer Won, Ji-Hee
 2008
 34 S1 p. 21-22
2 p.
 article
50 PL2.3. Adhesion molecules Yoneda, T.
 2008
 34 S1 p. 2-
1 p.
 article
51 PL8.1. Bisphosphonates: Where do they go and what do they do? Roelofs, A.
 2008
 34 S1 p. 47-
1 p.
 article
52 PL5 Bone biology and the Bone Microenvironment 2008
 34 S1 p. 45-
1 p.
 article
53 PL6.2. Bone cell–tumor cell interactions in prostate cancer Corey, E.
 2008
 34 S1 p. 46-
1 p.
 article
54 PL8.3. Bone targeted therapy Coleman, R.
 2008
 34 S1 p. 47-48
2 p.
 article
55 PL4.3. Circulating Tumour cells and tumour DNA Smerage, J.
 2008
 34 S1 p. 45-
1 p.
 article
56 PL1.3. Developments in bone target treatment of cancer Roodman, G. David
 2008
 34 S1 p. 1-
1 p.
 article
57 PL7.1. Developments in Preclinical Imaging Löwik, C.
 2008
 34 S1 p. 46-
1 p.
 article
58 PL4.1. Genetic predisposition to bone disease Ralston, S.
 2008
 34 S1 p. 45-
1 p.
 article
59 PL4.2. Genetic signatures and prediction of bone metastasis Klijn, J.
 2008
 34 S1 p. 45-
1 p.
 article
60 PL9.2. Haematopoeitic cell and growth factor – tumour cell interactions Weilbacher, K.
 2008
 34 S1 p. 49-
1 p.
 article
61 PL9.3. Is the antitumour efficacy of bisphosphonates clinically relevant? Holen, I.
 2008
 34 S1 p. 49-
1 p.
 article
62 PL2.1. M for invasion: Morphology, mutation and the microenvironment Anderson, A.
 2008
 34 S1 p. 1-2
2 p.
 article
63 PL6.1. Osteoblast activation in solid tumours Cecchini, M.
 2008
 34 S1 p. 3-4
2 p.
 article
64 PL5.2. Osteoblast inactivation in myeloma Matsumoto, T.
 2008
 34 S1 p. 45-
1 p.
 article
65 PL7.2. PET and bone metastases Fogelman, I.
 2008
 34 S1 p. 4-5
2 p.
 article
66 PL4 Prediction of bone disease and metastasis 2008
 34 S1 p. 45-
1 p.
 article
67 PL1.1. Preparing the soil – the bone marrow niche Mundy, G.
 2008
 34 S1 p. 43-
1 p.
 article
68 PL3.1. Prostate cancer stem cells and the metastatic process Maitland, N.
 2008
 34 S1 p. 45-
1 p.
 article
69 PL9.4. Protecting the normal skeleton – who, when and why Smith, M.
 2008
 34 S1 p. 49-
1 p.
 article
70 PL2.2. Proteolytic enzymes Murphy, G.
 2008
 34 S1 p. 2-
1 p.
 article
71 PL2.4. PTHrP and non-collagenous bone proteins Gillespie, M.
 2008
 34 S1 p. 44-
1 p.
 article
72 PL8.4. Radioisotope treatment of bone metastases Bruland, O.
 2008
 34 S1 p. 48-
1 p.
 article
73 PL5.1. RANK ligand signaling system in malignancy Croucher, P.
 2008
 34 S1 p. 45-
1 p.
 article
74 PL9.1. The importance of patient reported outcomes (PROs) in determining efficacy of treatment Fallowfield, L.
 2008
 34 S1 p. 48-49
2 p.
 article
75 PL1.2. Tumour-bone cell interactions in malignancy Guise, T.
 2008
 34 S1 p. 43-
1 p.
 article
76 PL8.2. Use of biochemical markers to monitor therapy in metastatic bone disease Garnero, P.
 2008
 34 S1 p. 4-
1 p.
 article
77 PL3.2. Wnt signaling in malignancy Clines, G.
 2008
 34 S1 p. 2-
1 p.
 article
78 P57. Manipulating the bone mineral affinity of bisphosphonates to directly target cancer cells in the bone marrow Daubiné, Florence
 2008
 34 S1 p. 42-
1 p.
 article
79 P18. Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid Ottewell, Penelope
 2008
 34 S1 p. 19-
1 p.
 article
80 P34. Melanoma-induced osteolysis is directly mediated through osteoclast formation and activity Edwards, James
 2008
 34 S1 p. 25-
1 p.
 article
81 P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover Coleman, Robert
 2008
 34 S1 p. 43-
1 p.
 article
82 P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells Pollari, Sirkku
 2008
 34 S1 p. 22-
1 p.
 article
83 P80. Minimally invasive treatment of tumour related vertebral compression fractures and other metastatic bone lesions Sinclair, Emily
 2008
 34 S1 p. 42-43
2 p.
 article
84 P27. Molecular interactions of disseminated tumor cells with the microenvironment of the bone marrow Schueler, Yvonne
 2008
 34 S1 p. 23-
1 p.
 article
85 P21. Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma Bates, Andreia
 2008
 34 S1 p. 20-
1 p.
 article
86 P44. Negative prognostic genes are induced by procollagen COOH trimer in breast carcinoma cells and angiogenesis is induced in xenograft tumors Palmieri, Daniela
 2008
 34 S1 p. 30-
1 p.
 article
87 P30. New models of osteoblastic bone metastasis: VCaP and DuCaP prostate cancer cell lines Schwaninger, Ruth
 2008
 34 S1 p. 24-25
2 p.
 article
88 P78. NHS resource use and capacity planning in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid Grieve, Robert
 2008
 34 S1 p. 84-85
2 p.
 article
89 P63. Not a tumour of bone: Just osteopoikilosis Toker, Serdar
 2008
 34 S1 p. 31-32
2 p.
 article
90 P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo Hirsh, Vera
 2008
 34 S1 p. 42-
1 p.
 article
91 P75. One-hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults Graziani, Silvia Regina
 2008
 34 S1 p. 35-36
2 p.
 article
92 P8. Osteoclast dysfunction in CD47−/− mice suppresses metastatic tumor burden and osteolysis Uluckan, Ozge
 2008
 34 S1 p. 15-16
2 p.
 article
93 P53. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: Initial dental safety findings from the AZURE study Burkinshaw, Roger
 2008
 34 S1 p. 40-41
2 p.
 article
94 P50. Osteotropic poly(d,l-lactide-co-glycolide)-alendronate nanoparticles for the treatment of bone cancer Cenni, Elisabetta
 2008
 34 S1 p. 38-
1 p.
 article
95 Poster Withdrawn 2008
 34 S1 p. 15-
1 p.
 article
96 P73. Pain flare following radiotherapy for painful bone metastases: A joint effort of three cancer centres to determine the incidence van Draanen, Jenna
 2008
 34 S1 p. 34-35
2 p.
 article
97 P76. Physiotherapy in metastatic tumors of humerus: A report of three cases Jamshidi Fard, Ali Reza
 2008
 34 S1 p. 84-
1 p.
 article
98 P4. Poorly structured bone matrix, reminiscent of an “osteoblastic” lesion, promotes an aggressive gene expression profile in prostate carcinoma cells in vitro Delany, Anne
 2008
 34 S1 p. 13-
1 p.
 article
99 P66. Poster Withdrawn 2008
 34 S1 p. 32-
1 p.
 article
100 P12. Poster Withdrawn 2008
 34 S1 p. 17-
1 p.
 article
101 P62. Prognostic variables for occurrence of skeletal-related events (SREs) in patients with breast cancer metastatic to bone: A multivariate analysis Brown, Janet
 2008
 34 S1 p. 28-
1 p.
 article
102 P2. Proteasome inhibition enhances anti-myeloma and anti-osteoclastic effects of glucocorticoids and weakens the anti-osteoblastic effects Soe, Kent
 2008
 34 S1 p. 13-
1 p.
 article
103 P46. Proteoglycans are potential regulators of osteoprotegerin (OPG) antitumoral and anti-bone resorption activities in osteosarcoma Lamoureux, François
 2008
 34 S1 p. 36-37
2 p.
 article
104 P38. RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 and regulates MMP1 and MMP9 expression Casimiro, Sandra
 2008
 34 S1 p. 27-28
2 p.
 article
105 P39. Rapamycin and the downstream target of mTOR, ribosomal protein L29 (RPL29), regulate prostate cancer cell growth and bone metastatic potential Schwarting-Opdenaker, Lynn
 2008
 34 S1 p. 70-
1 p.
 article
106 P51. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer Mulivor, Aaron
 2008
 34 S1 p. 39-40
2 p.
 article
107 P31. Real-time imaging of signaling pathway activity in osteotropic cancers in vivo van der Horst, Geertje
 2008
 34 S1 p. 24-
1 p.
 article
108 President’s Welcome Coleman, Robert
 2008
 34 S1 p. S1-
1 p.
 article
109 P19. Role of noggin in osteolytic bone metastasis Secondini, Chiara
 2008
 34 S1 p. 20-
1 p.
 article
110 P33. Role of SMAD2 and SMAD3 in breast cancer metastasis to bone Petersen, Maj
 2008
 34 S1 p. 25-26
2 p.
 article
111 P60. Skeletal metastases in malignant melanoma Kandukurti, Kiran
 2008
 34 S1 p. 18-
1 p.
 article
112 P64. Skeletal related events (SREs) in patients with bone metastases from breast cancer treated with intravenous (i.v.) bisphosphonates (BPs) in the non-trial setting Trinkaus, Mateya
 2008
 34 S1 p. 31-
1 p.
 article
113 P25. TACE up-regulation in monocytes by GM-CSF and IL-4 disrupts myeloma cell-induced osteoclastogenesis while inducing dendritic cell differentiation Abe, Masahiro
 2008
 34 S1 p. 22-23
2 p.
 article
114 P55. Targeting of αv integrins in prostate cancer and bone stroma inhibits bone metastasis formation and progression van der Horst, Geertje
 2008
 34 S1 p. 41-42
2 p.
 article
115 P56. Targeting VEGF and its receptors in the treatment of breast cancer bone metastases Bachelier, Richard
 2008
 34 S1 p. 41-
1 p.
 article
116 P7. The ADP receptor P2Y12 is expressed in developing osteoclasts and is required for full osteoclast function and tumor associated osteolysis Floyd, Desiree
 2008
 34 S1 p. 15-
1 p.
 article
117 P71. The bone degradation marker CTX is a unique marker for disease progression in multiple myeloma Lund, Thomas
 2008
 34 S1 p. 33-
1 p.
 article
118 P24. The effect of platycodin D on tumor-induced osteolysis in breast cancer bone metastasis Lee, Sun Kyoung
 2008
 34 S1 p. 22-
1 p.
 article
119 P52. The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo Idris, Aymen
 2008
 34 S1 p. 75-
1 p.
 article
120 P37. The in vivo impact of host MMP-2 to mammary tumor growth induced osteolysis Thiolloy, Sophie
 2008
 34 S1 p. 27-
1 p.
 article
121 P13. The RANKL inhibitor OPG-Fc delays the de novo establishment of breast cancer skeletal metastases in an MDA-MB-231 mouse model Canon, Jude
 2008
 34 S1 p. 17-
1 p.
 article
122 P47. Therapeutic efficacy of soluble receptor activator of NF-kappaB delivered by non-viral gene transfer in a mouse model of osteolytic osteosarcoma Lamoureux, François
 2008
 34 S1 p. 37-
1 p.
 article
123 P36. The role of FGF-signalling in osteosarcoma: A potential therapeutic target? Weekes, Daniel
 2008
 34 S1 p. 26-
1 p.
 article
124 P45. TNF-related apoptosis-inducing ligand (TRAIL) inhibits primary bone tumor growth and augments survival in a human model Ewing sarcoma Geffroy, Loic
 2008
 34 S1 p. 36-
1 p.
 article
125 P48. Transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases Mohammad, Khalid
 2008
 34 S1 p. 37-38
2 p.
 article
126 P32. Transforming growth factor-β (TGF-β) promotes prostate cancer bone metastases: Increased expression of pro-osteolytic genes and of PMEPA1, a new TGF-β signalling regulator Fournier, Pierrick
 2008
 34 S1 p. 25-
1 p.
 article
127 P29. Validation of an in vitro method to study the interactions between bone and prostate cancer cells Tieva, Ase
 2008
 34 S1 p. 24-
1 p.
 article
128 P68. Which IV bisphosphonates must be used after initiating androgen deprivation therapy in patients submitted to radical prostatectomy experiencing recurrence? A prospective open-label controlled study Rodrigues, Paulo
 2008
 34 S1 p. 32-
1 p.
 article
129 P35. Wnt signaling regulates Gli2 expression in human breast cancer cells that cause osteolysis Sterling, Julie
 2008
 34 S1 p. 26-27
2 p.
 article
130 P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with γδ T-cell mediated cancer cell death Monkkonen, Hannu
 2008
 34 S1 p. 37-
1 p.
 article
131 P15. Zoledronic acid modulates chromosome separation in breast cancer cells by inhibition of Cenp-F prenylation Brown, Hannah K.
 2008
 34 S1 p. 18-19
2 p.
 article
                             131 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands